Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1.

McElroy AK, Shrivastava-Ranjan P, Harmon JR, Martines RB, Silva-Flannery L, Flietstra TD, Kraft CS, Mehta AK, Lyon GM, Varkey JB, Ribner BS, Nichol ST, Zaki SR, Spiropoulou CF.

Emerg Infect Dis. 2019 Feb;25(2):290-298. doi: 10.3201/eid2502.181326.

2.

Ebola Infection in Pregnancy: A Global Perspective and Lessons Learned.

Haddad LB, Horton J, Ribner BS, Jamieson DJ.

Clin Obstet Gynecol. 2018 Mar;61(1):186-196. doi: 10.1097/GRF.0000000000000332. Review.

3.

Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.

Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M, Strecker T, Brown S, Patel K, De Leuw P, Schuettfort G, Stephan C, Rabenau H, Klena JD, Rollin PE, McElroy A, Ströher U, Nichol S, Kraft CS, Wolf T; Emory Serious Communicable Diseases Unit.

Clin Infect Dis. 2017 Sep 1;65(5):855-859. doi: 10.1093/cid/cix406.

4.

A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Jun 15;215(12):1862-1872. doi: 10.1093/infdis/jix201.

5.

The National Ebola Training and Education Center: Preparing the United States for Ebola and Other Special Pathogens.

Kratochvil CJ, Evans L, Ribner BS, Lowe JJ, Harvey MC, Hunt RC, Tumpey AJ, Fagan RP, Schwedhelm MM, Bell S, Maher J, Kraft CS, Cagliuso NV Sr, Vanairsdale S, Vasa A, Smith PW.

Health Secur. 2017 May/Jun;15(3):253-260. doi: 10.1089/hs.2017.0005.

6.

Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings.

Marshall Lyon G, Mehta AK, Ribner BS.

Curr Top Microbiol Immunol. 2017;411:115-137. doi: 10.1007/82_2017_19. Review.

PMID:
28601946
7.

Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor.

Shantha JG, Crozier I, Varkey JB, Kraft CS, Lyon GM 3rd, Mehta AK, Carlson RD, Hill CE, Kumar G, Debiec MR, Patel PS, Olsen TW, Nussenblatt RB, Martin DF, Ströher U, Uyeki TM, Ribner BS, Smith JR, Yeh S.

Ophthalmology. 2016 Dec;123(12):2626-2628.e2. doi: 10.1016/j.ophtha.2016.07.013. Epub 2016 Sep 1. No abstract available.

8.

Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST, Spiropoulou CF.

Clin Infect Dis. 2016 Aug 15;63(4):460-7. doi: 10.1093/cid/ciw334. Epub 2016 Jun 27. Erratum in: Clin Infect Dis. 2017 Aug 15;65(4):706.

9.

Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us.

Varkey JB, Ribner BS.

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0011-2016.

10.

Ebola Virus Persistence in Semen of Male Survivors.

Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Ströher U.

Clin Infect Dis. 2016 Jun 15;62(12):1552-1555. doi: 10.1093/cid/ciw202. Epub 2016 Apr 3.

PMID:
27045122
11.

Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa.

Stephens DS, Ribner BS, Gartland BD, Feistritzer NR, Farley MM, Larsen CP, Fox JT.

PLoS Med. 2015 Jul 28;12(7):e1001857. doi: 10.1371/journal.pmed.1001857. eCollection 2015 Jul.

12.

Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebolavirus from Contrived and Clinical Specimens.

Southern TR, Racsa LD, Albariño CG, Fey PD, Hinrichs SH, Murphy CN, Herrera VL, Sambol AR, Hill CE, Ryan EL, Kraft CS, Campbell S, Sealy TK, Schuh A, Ritchie JC, Lyon GM 3rd, Mehta AK, Varkey JB, Ribner BS, Brantly KP, Ströher U, Iwen PC, Burd EM.

J Clin Microbiol. 2015 Sep;53(9):2956-60. doi: 10.1128/JCM.01317-15. Epub 2015 Jul 8.

13.

Ebola virus disease: preparedness and infection control lessons learned from two biocontainment units.

Hewlett AL, Varkey JB, Smith PW, Ribner BS.

Curr Opin Infect Dis. 2015 Aug;28(4):343-8. doi: 10.1097/QCO.0000000000000176. Review.

14.

Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.

Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albariño CG, Reed Z, Cannon D, Ströher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM.

Ann Intern Med. 2015 Jul 21;163(2):81-90. doi: 10.7326/M15-0530.

15.

Persistence of Ebola Virus in Ocular Fluid during Convalescence.

Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S.

N Engl J Med. 2015 Jun 18;372(25):2423-7. doi: 10.1056/NEJMoa1500306. Epub 2015 May 7. Erratum in: N Engl J Med. 2015 Jun 18;372(25):2469.

16.

Environmental infection control considerations for Ebola.

Lowe JJ, Olinger PL, Gibbs SG, Rengarajan K, Beam EL, Boulter KC, Schwedhelm MM, Hayes AK, Kratochvil CJ, Vanairsdale S, Frislie B, Lewis J, Hewlett AL, Smith PW, Gartland B, Ribner BS.

Am J Infect Control. 2015 Jul 1;43(7):747-9. doi: 10.1016/j.ajic.2015.03.006. Epub 2015 Apr 29. No abstract available.

PMID:
25934067
17.

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.

Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit.

Clin Infect Dis. 2015 Aug 15;61(4):496-502. doi: 10.1093/cid/civ334. Epub 2015 Apr 22.

18.

Human Ebola virus infection results in substantial immune activation.

McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Ströher U, Damon I, Nichol ST, Spiropoulou CF, Ahmed R.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24. doi: 10.1073/pnas.1502619112. Epub 2015 Mar 9.

19.

Performance of bedside diagnostic ultrasound in an Ebola isolation unit: the Emory University Hospital experience.

Moreno CC, Kraft CS, Vanairsdale S, Kandiah P, Klopman MA, Ribner BS, Tridandapani S.

AJR Am J Roentgenol. 2015 Jun;204(6):1157-9. doi: 10.2214/AJR.15.14344. Epub 2015 Mar 2.

20.

Successful delivery of RRT in Ebola virus disease.

Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, Ströher U, Ribner BS, Franch HA.

J Am Soc Nephrol. 2015 Jan;26(1):31-7. doi: 10.1681/ASN.2014111057. Epub 2014 Nov 14.

21.

Clinical care of two patients with Ebola virus disease in the United States.

Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Ströher U, Uyeki TM, Ribner BS; Emory Serious Communicable Diseases Unit.

N Engl J Med. 2014 Dec 18;371(25):2402-9. doi: 10.1056/NEJMoa1409838. Epub 2014 Nov 12.

22.

A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations.

Llata E, Blossom DB, Khoury HJ, Rao CY, Wannemuehler KA, Noble-Wang J, Langston AA, Ribner BS, Lyon GM, Arnold KE, Jackson DR, Brandt ME, Chiller TM, Balajee SA, Srinivasan A, Magill SS.

Diagn Microbiol Infect Dis. 2011 Sep;71(1):72-80. doi: 10.1016/j.diagmicrobio.2010.12.022.

PMID:
21851872
23.

A Web-based program to ensure compliance of medical staff providers with mandated health care facility requirements.

Ribner BS, Hall C, Steinberg JP, Bornstein WA, Beasley K, Duffell JM, De Gennaro M, Garner D.

Am J Infect Control. 2011 Aug;39(6):511-4. doi: 10.1016/j.ajic.2010.08.021. Epub 2011 Apr 15.

PMID:
21496954
24.

Aminoglycoside-resistant Aeromonas hydrophila as part of a polymicrobial infection following a traumatic fall into freshwater.

Shak JR, Whitaker JA, Ribner BS, Burd EM.

J Clin Microbiol. 2011 Mar;49(3):1169-70. doi: 10.1128/JCM.01949-10. Epub 2011 Jan 5.

25.

Acute cholecystitis caused by nontoxigenic Vibrio cholerae O1 Inaba.

Vogt AP, Doshi RK, Higgins JE, Burd EM, Ribner BS, Kraft CS.

J Clin Microbiol. 2010 Mar;48(3):1002-4. doi: 10.1128/JCM.02198-09. Epub 2010 Jan 6.

26.

Cross-transmission of bacterial pathogens in the intensive care unit: What lessons can we learn?

Ribner BS, Steinberg JP.

Crit Care Med. 2010 Jan;38(1):302-3. doi: 10.1097/CCM.0b013e3181b4a44e. No abstract available.

PMID:
20023471
27.

Pseudo-outbreak of Legionella pneumophila serogroup 8 infection associated with a contaminated ice machine in a bronchoscopy suite.

Schuetz AN, Hughes RL, Howard RM, Williams TC, Nolte FS, Jackson D, Ribner BS.

Infect Control Hosp Epidemiol. 2009 May;30(5):461-6. doi: 10.1086/596613.

PMID:
19320573
28.

Use of a mandatory declination form in a program for influenza vaccination of healthcare workers.

Ribner BS, Hall C, Steinberg JP, Bornstein WA, Chakkalakal R, Emamifar A, Eichel I, Lee PC, Castellano PZ, Grossman GD.

Infect Control Hosp Epidemiol. 2008 Apr;29(4):302-8. doi: 10.1086/529586.

PMID:
18462141
29.

Influenza vaccination of health care workers: policies and practices of hospitals in a community setting.

Gazmararian JA, Coleman M, Prill M, Hinman AR, Ribner BS, Washington ML, Janssen A, Orenstein WA.

Am J Infect Control. 2007 Sep;35(7):441-7.

PMID:
17765555
30.

Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement.

Smith PW, Anderson AO, Christopher GW, Cieslak TJ, Devreede GJ, Fosdick GA, Greiner CB, Hauser JM, Hinrichs SH, Huebner KD, Iwen PC, Jourdan DR, Kortepeter MG, Landon VP, Lenaghan PA, Leopold RE, Marklund LA, Martin JW, Medcalf SJ, Mussack RJ, Neal RH, Ribner BS, Richmond JY, Rogge C, Daly LA, Roselle GA, Rupp ME, Sambol AR, Schaefer JE, Sibley J, Streifel AJ, Essen SG, Warfield KL.

Biosecur Bioterror. 2006;4(4):351-65.

PMID:
17238819
31.

Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D, et al.

Antimicrob Agents Chemother. 1993 Jun;37(6):1334-42.

32.

Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.

Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA, Kauffman CA, Yu VL.

Am J Med. 1993 Mar;94(3):313-28. Review.

PMID:
8452155
33.

Antibiotic resistance in long-term care facilities.

John JF Jr, Ribner BS.

Infect Control Hosp Epidemiol. 1991 Apr;12(4):245-50. No abstract available.

PMID:
1905739
34.

An effective educational program to reduce the frequency of needle recapping.

Ribner BS, Ribner BS.

Infect Control Hosp Epidemiol. 1990 Dec;11(12):635-8.

PMID:
2273226
35.

Outbreak of multiply resistant Staphylococcus aureus in a pediatric intensive care unit after consolidation with a surgical intensive care unit.

Ribner BS, Landry MN, Kidd K, Peninger M, Riddick J.

Am J Infect Control. 1989 Oct;17(5):244-9.

PMID:
2817513
37.

Impact of a rigid, puncture resistant container system upon needlestick injuries.

Ribner BS, Landry MN, Gholson GL, Linden LA.

Infect Control. 1987 Feb;8(2):63-6.

PMID:
3104225
38.
39.

Empirical use of imipenem as the sole antibiotic in the treatment of serious infections.

Freimer EH, Donabedian H, Raeder R, Ribner BS.

J Antimicrob Chemother. 1985 Oct;16(4):499-507.

PMID:
3864777
40.

Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.

Gross ML, Somani P, Ribner BS, Raeader R, Freimer EH, Higgins JT Jr.

Clin Pharmacol Ther. 1983 Nov;34(5):673-80.

PMID:
6313276
41.

T lymphocyte abnormalities in disseminated histoplasmosis.

Lehmann PF, Gibbons J, Senitzer D, Ribner BS, Freimer EH.

Am J Med. 1983 Nov;75(5):790-4.

PMID:
6227237
42.
43.

Treatment of serious infections with moxalactam.

Ribner BS, Raeder R, Becker TM, Freimer EH.

Am J Med. 1983 Mar;74(3):396-400.

PMID:
6219576
44.

Osteomyelitis caused by viridans streptococci.

Ribner BS, Freimer EH.

Arch Intern Med. 1982 Sep;142(9):1739.

PMID:
7114995
45.

Treatment of significant bacterial infections in adults with cefoxitin.

Ribner BS, Billiard BS, Freimer EH.

Rev Infect Dis. 1979 Jan-Feb;1(1):152-7.

PMID:
318216
46.

Oxolinic acid for the treatment of chronic gastrointestinal Shigella carriers.

Ribner BS, Freimer EH.

Am J Trop Med Hyg. 1978 Jul;27(4):840-2.

PMID:
686252
47.

Clinical experience with cefoxitin sodium.

Ribner BS, Freimer EH, Billiard BS.

J Antimicrob Chemother. 1978 Jul;4(B):209-10. No abstract available.

PMID:
357388
48.

Clinical studies with cefazolin: a new cephalosporin antibiotic.

Hammer GS, Ribner BS, Meyers BR, Hirschman SZ.

Mt Sinai J Med. 1975 Mar-Apr;42(2):142-9. No abstract available.

PMID:
1079566

Supplemental Content

Loading ...
Support Center